Stockpolly
Search
GRCE · NASDAQ · Biotechnology

Grace Therapeutics (GRCE)

Developing alternative-delivery therapies from established drugs.

$2.14
Pre-market0.00 (0.00%)
At close$2.14(+1.90%)
Watchlist

In millions of USD, except per-share figures

In millionsQ2 FY24Sep 2023Q3 FY24Dec 2023Q4 FY24Mar 2024Q1 FY25Jun 2024Q2 FY25Sep 2024Q3 FY25Dec 2024Q4 FY25Mar 2025Q1 FY26Jun 2025Q2 FY26Sep 2025Q3 FY26Dec 2025Q4 FY26Mar 2026Q1 FY27Jun 2026
Cost of revenue000000000000
Gross profit000000000000
3447555343316
Research & development122433211101
222322223302
Selling & marketing000000000000
General & administrative222322223302
Other expenses0000000000213
Operating income−3−4−4−7−5−5−5−3−4−3−3−16
−21−121−2402000
Interest income000000000000
Income before tax−5−3−6−5−4—−1−3−1−3−3−16
Income tax expense−10−1−1−1−1−1000−20
Net income from continuing operations−4−3−4−4−3−61−3−1−3−1−16
Net income−4−3−4−4−3−61−3−1−3−1−16
EPS, basic−$0.59−$0.28−$0.42−$0.33−$0.30−$0.52$0.06−$0.21−$0.08−$0.19−$0.07−$0.91
EPS, diluted−$0.59−$0.28−$0.42−$0.33−$0.30−$0.52$0.06−$0.21−$0.08−$0.19−$0.07−$0.91
Weighted average shares, basic81210111212141616171717
Weighted average shares, diluted81210111212141616171717
EBITDA—−4−4−7−5−5−5−3−4−3−3−16
Depreciation & amortization000000000000
EBIT−3−4−4−7−5−5−5−3−4−3−3−16